Outset Medical, Inc. (NASDAQ:OM) Shares Acquired by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC grew its stake in Outset Medical, Inc. (NASDAQ:OM) by 1,317.7% in the fourth quarter, Holdings Channel reports. The fund owned 8,790 shares of the company’s stock after purchasing an additional 8,170 shares during the period. Nisa Investment Advisors LLC’s holdings in Outset Medical were worth $48,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Assenagon Asset Management S.A. acquired a new stake in shares of Outset Medical in the 3rd quarter worth $6,807,000. FMR LLC grew its holdings in shares of Outset Medical by 1.1% during the 3rd quarter. FMR LLC now owns 7,468,531 shares of the company’s stock worth $81,258,000 after purchasing an additional 84,320 shares during the period. Braidwell LP grew its holdings in shares of Outset Medical by 64.4% during the 3rd quarter. Braidwell LP now owns 2,400,427 shares of the company’s stock worth $26,117,000 after purchasing an additional 940,059 shares during the period. Eagle Health Investments LP grew its holdings in shares of Outset Medical by 24.5% during the 3rd quarter. Eagle Health Investments LP now owns 1,494,514 shares of the company’s stock worth $16,260,000 after purchasing an additional 294,129 shares during the period. Finally, Swiss National Bank grew its holdings in shares of Outset Medical by 6.6% during the 3rd quarter. Swiss National Bank now owns 102,800 shares of the company’s stock worth $1,118,000 after purchasing an additional 6,400 shares during the period.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. BTIG Research assumed coverage on Outset Medical in a report on Monday, April 8th. They set a “buy” rating and a $6.00 price target for the company. Royal Bank of Canada cut Outset Medical from an “outperform” rating to a “sector perform” rating and lowered their target price for the company from $14.00 to $6.00 in a report on Friday, January 12th. Finally, CL King upgraded Outset Medical from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a report on Friday, April 5th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $5.42.

Outset Medical Price Performance

Shares of NASDAQ OM opened at $2.32 on Monday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 4.37 and a current ratio of 5.26. Outset Medical, Inc. has a fifty-two week low of $1.92 and a fifty-two week high of $24.13. The firm has a market capitalization of $119.95 million, a PE ratio of -0.66 and a beta of 1.99. The stock’s 50-day simple moving average is $2.64 and its 200-day simple moving average is $4.06.

Outset Medical (NASDAQ:OM) last issued its earnings results on Wednesday, February 21st. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.03). Outset Medical had a negative return on equity of 102.50% and a negative net margin of 132.54%. The business had revenue of $30.51 million for the quarter, compared to analyst estimates of $30.40 million. As a group, equities research analysts forecast that Outset Medical, Inc. will post -2.28 EPS for the current fiscal year.

Outset Medical Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.